A Phase II Trial of Epirubicin/Docetaxel in the First-Line Treatment of Patients With Metastatic Breast Cancer
Upon determination of eligibility, all patients will receive:
Docetaxel + Epirubicin
Both drugs will be repeated at 21-day intervals
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Clinical response rate of the docetaxel/epirubicin combination in the first-line treatment of patients with metastatic breast cancer
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI BRE 39
NCT00193024
September 2001
October 2004
Name | Location |
---|